Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Q3 Results Preview: Pfizer, Allergan, Sanofi, Teva & AstraZeneca

Executive Summary

Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.


Related Content

Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
Sanofi and Regeneron Hit Asthma Phase III Endpoints With Dupixent
AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory
Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race
What does Actavis get in $66bn Allergan buy?
Strike three: Allergan slides on potential Restasis generics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts